Patent ID: 7943311
Filing Date: 2011-05-17
Classification: C12Q

Abstract:
1. A method for determining the risk of adverse effects of irinotecan comprising: amplifying a target region of a nucleic acid sample obtained from a subject at risk of experiencing adverse effects of irinotecan, wherein said target region comprises the TATA box within the promoter region of the UDP glucuronosyl transferase (UGT1A1) gene; hybridizing to the amplified nucleic acid at least one pair of nucleic acid probes selected from the group of probes a and b, c and d, e and f, a and f, and e and b, measuring the ratio between the amount of nucleic acid hybridized to each individual probe in a pair of probes a/b, c/d, and e/f; and determining a lower risk of adverse effects to irinotecan when the ratio of b/a, d/c, f/e, f/a, b/e is high compared to a subject having a lower ratio; wherein said method comprises: hybridizing the nucleic acid probe pair a and b; wherein probe a consists of the nucleotide sequence of SEQ ID NO: 3 and probe b consists of the nucleotide sequence of either SEQ ID NO: 4 or NO: 17, or alternatively probe a consists of the nucleotide sequence of SEQ ID NO: 5 and probe b consists of the nucleotide sequence of SEQ ID NO: 6; hybridizing the nucleic acid probe pair c and d; wherein probe c consists of the nucleotide sequence of SEQ ID NO: 7 and probe d consists of the nucleotide sequence of SEQ ID NO: 8, or alternatively probe c consists of the nucleotide sequence of SEQ ID NO: 9 and probe d consists of the nucleotide sequence of SEQ ID NO: 10; hybridizing the nucleic acid probe pair e and f; wherein probe e consists of the nucleotide sequence of SEQ ID NO: 18 and probe f consists of the nucleotide sequence of SEQ ID NO: 19; hybridizing the nucleic acid probe pair a and b; wherein probe a consists of the nucleotide sequence of SEQ ID NO: 3 with one or two-nucleotide deletion at its 3′ and/or 5′ end and probe b consists of the nucleotide sequence of either SEQ ID NO: 4 or NO: 17 with one or two-nucleotide deletion at its 3′ and/or 5′ end, or alternatively probe a consists of the nucleotide sequence of SEQ ID NO: 5 with one or two-nucleotide deletion at its 3′ and/or 5′ end and probe b consists of the nucleotide sequence of SEQ ID NO:6 with one or two-nucleotide deletion at its 3′ and/or 5′ end; hybridizing the nucleic acid probe pair c and d; wherein c consists of the nucleotide sequence of SEQ ID NO: 7 with one or two-nucleotide deletion at its 3′ and/or 5′ end and probe d consists of the nucleotide sequence of SEQ ID NO: 8 with one or two-nucleotide deletion at its 3′ and/or 5′ end, or alternatively probe c consists of the nucleotide sequence of SEQ ID NO: 9 with one or two-nucleotide deletion at its 3′ and/or 5′ end and probe d consists of the nucleotide sequence of SEQ ID NO: 10 with one or two-nucleotide deletion at its 3′ and/or 5′ end; or hybridizing the nucleic acid probe pair e and f; wherein probe e consists of the nucleotide sequence of SEQ ID NO: 18 with one or two-nucleotide deletion at its 3′ and/or 5′ end and probe f consists of the nucleotide sequence of SEQ ID NO: 19 with one or two-nucleotide deletion at its 3′ and/or 5′ end.